Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-07-29
2009-12-15
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S178100
Reexamination Certificate
active
07632927
ABSTRACT:
A radioimmunoconjugate for targeted alpha therapy comprises an alpha-emitter (e.g. Bi-213) linked to the monoclonal antibody C595. This radioimmunoconjugate is widely applicable in cancer therapy and is particularly efficient for treatment of pancreatic and prostate cancer, as well as for breast and ovarian cancer.
REFERENCES:
patent: WO 02/22685 (2002-03-01), None
Allen et al. (Crit. Rev. Oncol. Hematol. vol. 39(1-2), pp. 139-146), 2001).
Denton et al. (Br. J. Cancer, vol. 76(5), pp. 614-621, 1997).
Allen et al. (Crit. Rev. Oncol. Hematol. vol. 39(1-2), pp. 139-146), 2001) Abstract only.
Denton et al. (Br. J. Cancer, vol. 76(5), pp. 614-621, 1997) Abstract only.
Murray et al. (J of Nuclear Medicine, vol. 42, pp. 726-732, 2001).
Allen et al. (Critical Reviews in Onc./Hematology, vol. 39, pp. 139-146, 2001).
Perkins Alan et al; “Antibody conjugate radioimmunotherapy of superficial bladder cancer.”; Brazilian Archives of Biology and Technology; vol. 45, No. Special Issue, Sep. 2002, pp. 87-89, XP001204515; ISSN: 1516-8913.
Lo Benny: “Biotherapy” European Journal of Cancer, Pergamon Press, Oxford, GB, vol. 37, Oct. 2001, p. 228, XP004359247; ISSN: 0959-8049.
Seyed K I: “Advancements in cancer therapy with alpha-emitters: a review” International Journal of Radiation: Oncology Biology Physics, Pergamon Press, US, vol. 51, No. 1, Sep. 1, 2001, pp. 271-278, XP002206123; ISSN: 0360-3016.
Allen Barry
Li Yong
On Chang Fa
Rizvi Syed
Cantor & Colburn LLP
Helms Larry R.
Natarajan Meera
The European Community, as Represented by the European Commision
LandOfFree
Radioimmunoconjugates for targeted alpha therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radioimmunoconjugates for targeted alpha therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioimmunoconjugates for targeted alpha therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112720